Table 1.
Demographic and Clinical Features of the Studied Cohort
| AMD Cohort | |
|---|---|
| No. of patients (no. of eyes) | 42 (64) |
| Age, years | 71.4 ± 6.8 |
| Sex | |
| Male | 11 (26.2) |
| Female | 31 (73.8) |
| Ethnicity | |
| White, Not Hispanic | 35 (83.3) |
| Other or Hispanic | 7 (16.7) |
| Smoking Status | |
| Current | 0 (0) |
| Former | 21 (50.0) |
| Never | 20 (47.6) |
| Unknown | 1 (2.4) |
| AREDS2 supplement | 37 (88.1) |
| Statin use | 28 (66.7) |
| Lens Status | |
| Phakic | 43 (67.2) |
| Pseudophakic | 21 (32.8) |
| Follow-up duration | 37.4 ± 9.0 |
| ETDRS Baseline VA (Snellen) | 78.5 ± 7.8 (20/27) |
| AMD Stage | |
| Early, eyes | 13 (20.3) |
| Intermediate, eyes | 51 (79.7) |
ETDRS, Early Treatment for Diabetic Retinopathy Study; VA, visual acuity.
Values are mean ± SD or number (%) unless otherwise indicated.